The ADMA/DDAH Pathway Regulates VEGF-Mediated Angiogenesis | Zendy

Lorna R. Fiedler | Zendy; Tiziana Bachetti | Zendy; James Leiper | Zendy; Ian Zachary | Zendy; Lihua Chen | Zendy; Thomas Renné | Zendy; Beata WójciakStothard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The ADMA/DDAH Pathway Regulates VEGF-Mediated Angiogenesis

Author(s) -

Lorna R. Fiedler,

Tiziana Bachetti,

James Leiper,

Ian Zachary,

Lihua Chen,

Thomas Renné,

Beata WójciakStothard

Publication year - 2009

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.109.194035

Subject(s) - angiogenesis , vegf receptors , cancer research , medicine , chemistry

Asymmetrical dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor and cardiovascular risk factor associated with angiogenic disorders. Enzymes metabolising ADMA, dimethylarginine dimethylaminohydrolases (DDAH) promote angiogenesis, but the mechanisms are not clear. We hypothesized that ADMA/DDAH modifies endothelial responses to vascular endothelial growth factor (VEGF) by affecting activity of Rho GTPases, regulators of actin polymerization, and focal adhesion dynamics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research